“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial of nivolumab, ipilimumab and chemotherapy for advanced lung cancer (CA209227)
Cancer type:
Status:
Phase:
This trial was for people with non small cell lung cancer (NSCLC) that had spread to another part of the body.
This trial was open for people to join between August 2015 and November 2016.
These results were published in 2018 .
More about this trial
Chemotherapy is the usual treatment for advanced NSCLC. But for some people this might not work well. This is because of certain proteins on the cancer cells. These proteins can stop the body’s immune system attacking cancer cells.
One protein is PD-L1. Nivolumab is a targeted cancer drug. It works by blocking PD-L1. We knew from research that nivolumab helped people with NSCLC.
In this trial the team looked at the following treatments:
- nivolumab
- nivolumab and ipilimumab
- nivolumab and chemotherapy
- chemotherapy
- how well the above treatments worked for NSCLC
- how safe the above treatments were for people with NSCLC
- how acceptable people found the above treatments
Summary of results
- nivolumab and ipilimumab
- nivolumab
- chemotherapy (pemetrexed combined with either cisplatin or carboplatin)
- 396 had nivolumab and ipilimumab
- 396 had nivolumab
- 397 had chemotherapy
And of the 550 people whose cancer tissue sample had PDL-1 protein in less than 1 part of every 100 parts (less than 1%):
- 187 had nivolumab and ipilimumab
- 177 had nivolumab and chemotherapy
- 186 had chemotherapy
- 139 had nivolumab and ipilimumab
- 160 had chemotherapy
- just under 31 out of every 100 people (30.9%) in the nivolumab and ipilimumab group
- 17 out of every 100 people (17%) in the chemotherapy group
- just over 45 people out of every 100 (45.3%) in the nivolumab and ipilimumab group
- just under 27 people out of every 100 (26.9%) in the chemotherapy group
- just over 42 out of every 100 people (42.6%) in the nivolumab and ipilimumab group
- just over 13 out of every 100 people (13.2%) in the chemotherapy group
- just over 7 months (7.2) in the nivolumab and ipilimumab group
- 5 ½ months in the chemotherapy group
- just over 3 months (3.2) for those who had nivolumab and ipilimumab
- 5½ months for those who had chemotherapy
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr David Spicer
Supported by
Bristol-Myers Squibb
Experimental Cancer Medicine Centre (ECMC)
Ono Pharmaceutical Co. Ltd
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040